4-((4-(mesitylamino)-6-(3-morpholinopropoxy) pyrimidin-2-yl)amino)benzonitrile | 1452006-62-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((4-(mesitylamino)-6-(3-morpholinopropoxy) pyrimidin-2-yl)amino)benzonitrile
• 英文别名: 4-[[4-(3-Morpholinopropoxy)-6-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile；4-[[4-(3-morpholin-4-ylpropoxy)-6-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile
• CAS: 1452006-62-0
• 化学式: C₂₇H₃₂N₆O₂
• 分子量: 472.59
• InChiKey: VGQOQVGHPBIOJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  95.3
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-N[2(4,6-二氯吡啶基)]-氨基苯腈 在 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 4-((4-(mesitylamino)-6-(3-morpholinopropoxy) pyrimidin-2-yl)amino)benzonitrile
  参考文献：
  名称：

  Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility

  摘要：

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity. The solubility enhancements come from strategic placement of a morpholinylalkoxy substituent in the entrance channel of the NNRTI binding site. Compound 4d shows low-nanomolar activity similar to etravirine towards wild-type HIV-1 and key viral variants. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.091

文献信息

• Novel Compositions and Methods of Treating HIV-1 Infections Using Same
  申请人：YALE UNIVERSITY

  公开号：US20140378443A1

  公开（公告）日：2014-12-25

  The present invention includes novel compositions useful for preventing or treating an HIV-1 infection in a subject in need thereof. The present invention further includes a novel method of preventing or treating an HIV-1 infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the subject is further administered at least one additional therapeutic agent.

  本发明包括用于预防或治疗需要的受试者的HIV-1感染的新型组合物。本发明还包括一种用于预防或治疗需要的受试者的HIV-1感染的新方法，该方法包括向受试者施用本发明的化合物的有效量。在一个实施例中，受试者还被施用至少一种额外的治疗药物。
• US8933329B2
  申请人：——

  公开号：US8933329B2

  公开（公告）日：2015-01-13
• US9914709B2
  申请人：——

  公开号：US9914709B2

  公开（公告）日：2018-03-13
• Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility
  作者：Mariela Bollini、José A. Cisneros、Krasimir A. Spasov、Karen S. Anderson、William L. Jorgensen

  DOI：10.1016/j.bmcl.2013.06.091

  日期：2013.9

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity. The solubility enhancements come from strategic placement of a morpholinylalkoxy substituent in the entrance channel of the NNRTI binding site. Compound 4d shows low-nanomolar activity similar to etravirine towards wild-type HIV-1 and key viral variants. (C) 2013 Elsevier Ltd. All rights reserved.